Novo Nordisk stock news
On May 21, 2026, Novo Nordisk (NVO) announced a strategic partnership with OpenAI to integrate artificial intelligence across its drug discovery, manufacturing, and supply chain operations. This collaboration is intended to enhance research productivity and optimize production efficiency for its GLP--1 therapies, such as Wegovy and Ozempic, to better manage high demand and competitive pressures in the cardiometabolic market.